Kim Kramer
(Chief, Pediatric General Oncology) · New York Presbyterian Hospital
Credentials: · · ·
History
PresentPediatric General Oncology) Division · New York Presbyterian Hospital
Research
Tumour exosome integrins determine organotropic metastasis
Nature · 2015 · 4,149 citations
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Cell · 2020 · 1,025 citations
The Lancet Oncology · 2018 · 226 citations
- BK
92 papers
- SM
65 papers · 15 as a resident
- MQ
27 papers · 5 as a fellow
- EB
26 papers
- SW
Suzanne Wolden
23 papers
22 papers · 6 as a fellow
- NC
21 papers
- SL
20 papers
Grants
- 2006–2009
131-1 3f8 for Leptomeningeal Cancers
Food and Drug Administration · R01
Contact PI · $739.2K · Sloan-Kettering Inst Can Research
- 2005–2008
Treating CNS Malignancies with 131-I-8H9
National Cancer Institute · R21
Contact PI · $698.8K · Sloan-Kettering Inst Can Research
- 2000–2003
Intrathecal 131 i 3f8 for Leptomeningeal Malignancies
National Cancer Institute · R21
Contact PI · $749.3K · Sloan-Kettering Inst Can Research
- 1997–2002
Intrathecal Radioimmunotherapy of Cns Malignancies
National Cancer Institute · K08
Contact PI · $410.4K · Sloan-Kettering Inst Can Research
Clinical trials
- 2004–2022
Principal investigator · Terminated · Phase 1
Y-mAbs Therapeutics
- 2006–2023
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
- 1997–2005
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Study chair · Completed · Phase 1
Memorial Sloan Kettering Cancer Center